Oncodesign Precision Medicine (XPAR:ALOPM) Interest Expense: €-0.19 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
33 GF Score
Price €0.32
GF Value €0.29
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Interest Expense?

Oncodesign Precision Medicine XPAR:ALOPM 33 Interest Expense is €-0.19 Mil as of Dec. 2025. GuruFocus rates XPAR:ALOPM with a GF Score™ of 33/100 and a GF Value™ of €0.29 (Fairly Valued). The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oncodesign Precision Medicine's interest expense for the six months ended in Dec. 2025 was € 0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oncodesign Precision Medicine's Operating Income for the six months ended in Dec. 2025 was € -1.57 Mil. Oncodesign Precision Medicine's Interest Expense for the six months ended in Dec. 2025 was € 0.03 Mil. Oncodesign Precision Medicine did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncodesign Precision Medicine  (XPAR:ALOPM) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncodesign Precision Medicine's Interest Expense for the six months ended in Dec. 2025 was €0.03 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-1.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €6.36 Mil.

Oncodesign Precision Medicine's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Oncodesign Precision Medicine Interest Expense Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Interest Expense Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.36 -0.12 -0.15 -0.44 -0.19

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.22 -0.22 -0.21 0.03
XPAR:ALOPM
33GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.19 Mil mean?
Oncodesign Precision Medicine (XPAR:ALOPM) has a Interest Expense of €-0.19 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Interest Expense too high?
Oncodesign Precision Medicine's current Interest Expense is €-0.19 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Interest Expense compare to VRTX and REGN?
Oncodesign Precision Medicine's Interest Expense of €-0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Interest Expense is €-0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.32 — trading 10.3% above its estimated fair value. The current Interest Expense is €-0.19 Mil. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Interest Expense is €-0.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.32 is trading 10.3% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Fairly Valued.

Key valuation signals for XPAR:ALOPM:

  • Interest Expense: €-0.19 Mil
  • GF Value™: €0.29 vs. price of €0.32 (10.3% above fair value)
  • GF Score™: 33/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score

Get the complete analysis for XPAR:ALOPM

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€0.29
GF Value